Evidence map›Paper›PMID 30290590›Full record

ArticleMedicine2018

Malakoplakia as a cause of severe hypercalcemia through ectopic 25-hydroxyvitamin D3 1-alpha-hydroxylase expression: A case report.

Jonathan Maurice Chemouny, Aurélie Sannier, Guillaume Hanouna, Laure Champion, Francois Vrtovsnik, Eric Daugas

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Too much vitamin D? a drug safety review.Reviews in endocrine & metabolic disorders · 2026
    Review
  2. Malakoplakia of the Kidney Transplant.Kidney international reports · 2023
    Article
  3. BMJ case reports · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Jonathan Maurice ChemounyService de Néphrologie, Hôpital Bichat-Claude Bernard, AP-HP, DHU Fire.
Aurélie SannierUniversité Paris Diderot, Sorbonne Paris Cité.
Guillaume HanounaService de Néphrologie, Hôpital Bichat-Claude Bernard, AP-HP, DHU Fire.
Laure Champion
Francois VrtovsnikService de Néphrologie, Hôpital Bichat-Claude Bernard, AP-HP, DHU Fire.
Eric DaugasService de Néphrologie, Hôpital Bichat-Claude Bernard, AP-HP, DHU Fire.
Inserm · FRCentre de Recherche sur l'Inflammation · FRDélégation Paris 7 · FRSorbonne Paris Cité · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleMalakoplakia is a rare disease characterized by the presence of nongranulomatous macrophage infiltration. In most cases, it affects the urinary tract. Malakoplakia can cause acute kidney injury when it is localized in the kidneys. PATIENT CONCERNS: Here, we report the case of a 65-year-old female patient with renal malakoplakia responsible for hypercalcemia. During her initial assessment, she was also diagnosed 25-OH vitamin D insufficiency, for which she was prescribed oral cholecalciferol. Three months later, she developed severe hypercalcemia with normal 25-OH vitamin D and parathyroid hormone levels and high 1,25-dihydroxyvitamin D levels. DIAGNOSES: After a superimposed granulomatous disease was excluded, malakoplakia cells were suspected to be responsible for the abnormal 25-hydroxyvitamin D3 1-alpha-hydroxylase activity, which was confirmed by immunohistochemistry.

interventionsCholecalciferol was stopped, the patient was rehydrated with intravenous physiological saline, and prednisone was initiated to decrease the enzyme activity. OUTCOMES: Six months later, she displayed normal serum calcium, 25-OH vitamin D and 1,25-dihydroxyvitamin D levels. LESSONS: This case illustrates that malakoplakia may exhibit ectopic 25-hydroxyvitamin D3 1-alpha-hydroxylase activity and cause severe hypercalcemia upon vitamin D supplementation. Therefore, such supplementation should not be given in malakoplakia patients without an actual deficiency and requires careful monitoring of serum calcium.

Indexed as

25-Hydroxyvitamin D3 1-alpha-HydroxylaseAgedCalciumCholecalciferolDietary SupplementsEctopic Gene ExpressionFemaleHumansHypercalcemiaKidney DiseasesMalacoplakiaParathyroid HormoneVitamin D DeficiencyVitamins25-Hydroxyvitamin D3 1-alpha-HydroxylaseCalciumCholecalciferolCYP27B1 protein, humanParathyroid HormoneVitamins

Identifiers

PMID30290590
PMCPMC6200547
OpenAlexW2894906147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.